Citations

Showing 10 of 108104 citations.

Augmenting MRI Safety Screening Processes: Reliable Identification of Cardiac Implantable Electronic Devices by a Ferromagnetic Detector System
Watson, Robert E. , Walsh, S., Felmlee, Joel P. , Friedman, Paul A. , Keene, Mark N., Walsh, Suson M

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 26, 2018 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/jmri.26277 | PMID 30257050 Get It

Level of Evidence: 1Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2019;49:e297–e299.
ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
Reese, Jordan , Bruinsma, Elizabeth S. , Nelson, Adam W , Chernukhin, Igor , Carroll, Jason S. , Li, Ying , Subramaniam, Malayannan , Negron, Vivian , Hawse, John R. , Reese, Jordan M, Monroe, David G. , Ingle, James N. , Suman, Vera J. , Goetz, Matthew P.

Mayo Clinic

Proceedings of the National Academy of Sciences | September 26, 2018 | Volume: 115 | Issue: 41 | Pages: No page available

10.1073/pnas.1807751115 | PMID 30257941 Get It

Significance Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and patients exhibit high rates of recurrence and mortality in part due to lack of treatment options beyond standard-of-care chemotherapy regimens. In the subset of TNBCs that express estrogen receptor beta (ERβ), ligand-mediated activation of ERβ elicits potent anticancer effects. We report here the elucidation of the ERβ cistrome and transcriptome in TNBC and identify a mechanism whereby ERβ induces cystatin gene expression resulting in inhibition of canonical TGFβ signaling and a blockade of metastatic phenotypes. These findings suggest that ERβ-targeted therapies represent a treatment option for the subset of women with ERβ-expressing TNBC.
HCN1mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond
Marini, Carla , Porro, Alessandro , Rastetter, Agnès, Dalle, Carine, Rivolta, Ilaria , Bauer, Daniel , Oegema, Renske , Nava, Caroline , Parrini, Elena , Mei, Davide , Mercer, Catherine , Dhamija, Radhika , Chambers, Chelsea , Coubes, Christine, Kuentz, Paul , Julia, Sophie , Pasquier, Laurent , Dubourg, Christèle , Carré, Wilfrid , Melani, Federico , Giardino, Maria , Innes, A. Micheil , Alembik, Yves, Scheidecker, Sophie , Figueiroa, Sónia, Garrido, Cristina , Fusco, Carlo , Spagnoli, Carlotta , Binda, Anna , Granata, Tiziana , Ragona, Francesca , Freri, Elena , Franceschetti, Silvana , Canafoglia, Laura , Castellotti, Barbara , Gellera, Cinzia , Milanesi, Raffaella , Mancardi, Maria Margherita , Clark, Damien R, Helbig, Katherine L. , Ichikawa, Shoji , Sadler, Laurie S. , Neupauerová, Jana, Laššuthová, Petra , Štěrbová, Katalin , Laridon, Annick, Brilstra, Eva H. , Koeleman, Bobby P.C. , Striano, Pasquale, Soblet, Julie , Deconinck, Nicolas , Leguern, Éric , Guerrini, Renzo , Santoro, Bina , Hamacher, Kay , Moroni, Anna , DiFrancesco, Jacopo C. , Depienne, Christel , Guerrini, Renzo , Mei, Davide , Pasquier, Laurent , Thévenon, Julien , Rosati, Anna Maria , Pisano, Tiziana , Santos, Manuela M. , Frattini, Daniele , Clark, Damien R., Kok, Fernando , Lemke, Johannes R. , Zara, Federico , Smits, Guillaume , Barbuti, Andrea , DiFrancesco, Dario , Thiel, Gerhard , Depienne, Christel , Dhamija, Radhika

Mayo Clinic

Brain | September 26, 2018 | Volume: 141 | Issue: 11 | Pages: 3160-3178

10.1093/brain/awy263 | PMID 30351409 Get It

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection
Solanky, Dipesh , Pardi, Darrell S. , Loftus, Edward V. , Khanna, Sahil , Loftus, Edward V

Mayo Clinic

Inflammatory Bowel Diseases | September 26, 2018 | Volume: 25 | Issue: 3 | Pages: 610-619

10.1093/ibd/izy291 | PMID 30260451 Get It

Abstract Background Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy and CDI treatment. Methods Records for patients with IBD and CDI from 2008 to 2013 were abstracted for variables including IBD severity before CDI diagnosis, CDI management, subsequent IBD exacerbation, CDI recurrence, and colon surgery. Colon surgery was defined as resection of any colonic segment within 1 year after CDI diagnosis. Results We included 137 IBD patients (median age, 46 years; 55% women): 70 with ulcerative colitis (51%), 63 with Crohn’s disease (46%), and 4 with indeterminate colitis (3%). Overall, 70% of CDIs were mild-moderate, 14% were severe, and 15% were severe-complicated. Clostridium difficile infection treatment choice did not vary by infection severity (P = 0.27). Corticosteroid escalation (odds ratio [OR], 5.94; 95% confidence interval [CI], 2.03–17.44) was a positive predictor of colon surgery within 1 year after CDI; older age (OR, 0.09; 95% CI, 0.01–0.44) was a negative predictor. Modifying the corticosteroid regimen did not affect CDI recurrence or risk of future IBD exacerbation. Adverse outcomes did not differ with CDI antibiotic regimens or biologic or immunomodulator regimen modification. Conclusions Corticosteroid escalation for IBD during CDI was associated with higher risk of colon surgery. Type of CDI treatment did not influence IBD outcomes. Prospective studies are needed to further elucidate optimal management in this high-risk population.
Improving apparent diffusion coefficient accuracy on a compact 3T MRI scanner using gradient nonlinearity correction
Tao, Ashley , Shu, Yunhong , Trzasko, Joshua D. , Tao, Shengzhen , Reid, Robert D., Weavers, Paul T., Tao, Ashley T , Tao, Shengzhen , Tan, Ek T. , Huston, John , Bernstein, Matt A.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 26, 2018 | Volume: 48 | Issue: 6 | Pages: 1498-1507

10.1002/jmri.26201 | PMID 30255963 Get It

BackgroundGradient nonlinearity (GNL) leads to biased apparent diffusion coefficients (ADCs) in diffusion‐weighted imaging. A gradient nonlinearity correction (GNLC) method has been developed for whole body systems, but is yet to be tested for the new compact 3T (C3T) scanner, which exhibits more complex GNL due to its asymmetrical design.PurposeTo assess the improvement of ADC quantification with GNLC for the C3T scanner.Study TypePhantom measurements and retrospective analysis of patient data.Phantom/SubjectsA diffusion quality control phantom with vials containing 0–30% polyvinylpyrrolidone in water was used. For in vivo data, 12 patient exams were analyzed (median age, 33).Field Strength/SequenceImaging was performed on the C3T and two commercial 3T scanners. A clinical DWI (repetition time [TR] = 10,000 msec, echo time [TE] = minimum, b = 1000 s/mm2) sequence was used for phantom imaging and 10 patient cases and a clinical DTI (TR = 6000–10,000 msec, TE = minimum, b = 1000 s/mm2) sequence was used for two patient cases.AssessmentThe 0% vial was measured along three orthogonal axes, and at two different temperatures. The ADC for each concentration was compared between the C3T and two whole‐body scanners. Cerebrospinal fluid and white matter ADCs were quantified for each patient and compared to values in literature.Statistical TestsPaired t‐test and two‐way analysis of variance (ANOVA).ResultsFor all PVP concentrations, the corrected ADC was within 2.5% of the reference ADC. On average, the ADC of cerebrospinal fluid and white matter post‐GNLC were within 1% and 6%, respectively, of values reported in the literature and were significantly different from the uncorrected data (P < 0.05).Data ConclusionThis study demonstrated that GNL effects were more severe for the C3T due to the asymmetric gradient design, but our implementation of a GNLC compensated for these effects, resulting in ADC values that are in good agreement with values from the literature.Level of Evidence: 4Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018;48:1498–1507
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, William F. , Young, W F

Mayo Clinic

Journal of Internal Medicine | September 25, 2018 | Volume: 285 | Issue: 2 | Pages: 126-148

10.1111/joim.12831 | PMID 30255616 Get It

Abstract Primary aldosteronism ( PA ), the most common form of secondary hypertension, can be either surgically cured or treated with targeted pharmacotherapy. PA is frequently undiagnosed and untreated, leading to aldosterone‐specific cardiovascular morbidity and nephrotoxicity. Thus, clinicians should perform case detection testing for PA at least once in all patients with hypertension. Confirmatory testing is indicated in most patients with positive case detection testing results. The next step is to determine whether patients with confirmed PA have a disease that can be cured with surgery or whether it should be treated medically; this step is guided by computed tomography scan of the adrenal glands and adrenal venous sampling. With appropriate surgical expertise, laparoscopic unilateral adrenalectomy is safe, efficient and curative in patients with unilateral adrenal disease. In patients who have bilateral aldosterone hypersecretion, the optimal management is a low‐sodium diet and lifelong treatment with a mineralocorticoid receptor antagonist administered at a dosage to maintain a high–normal serum potassium concentration without the aid of oral potassium supplements.
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes
Cousminer, Diana L. , Ahlqvist, Emma , Mishra, Rajashree, Andersen, Mette K. , Chesi, Alessandra , Hawa, M. I., Davis, Asa K., Hodge, Kenyaita M., Bradfield, Jonathan P., Zhou, Kaixin , Guy, Vanessa C., Åkerlund, Mikael, Wod, Mette , Fritsche, Lars G. , Vestergaard, Henrik , Snyder, James W. , Højlund, Kurt , Linneberg, Allan , Käräjämäki, Annemari , Brandslund, Ivan , Kim, Cecilia E, Witte, Daniel R. , Sørgjerd, Elin Pettersen , Brillon, David J., Pedersen, Oluf , Beck‐Nielsen, Henning , Grarup, Niels , Rickels, Michael R. , Melander, Olle , Harris, Ronald I., Varvel, Stephen A. , Grill, Valdemar , Håkonarson, Håkon , Froguel, Philippe , Lonsdale, John T., Mauricio, Dı́dac , Schloot, Nanette C. , Khunti, Kamlesh , Greenbaum, Carla J. , Åsvold, Bjørn Olav , Yderstræde, Knud Bonnet , Pearson, Ewan R. , Schwartz, Stanley S. , Voight, Benjamin F. , Hansen, Torben , Tuomi, Tiinamaija , Boehm, Bernhard O. , Groop, Leif , Leslie, Richard David , Grant, Struan F.A. , Study, Bone Mineral Density in Childhood, Mitchell, Jonathan A. , Lappe, Joan M. , Gilsanz, Vicente , Rickels, Michael R , Vella, Adrian , Hakonarson, Hakon , Mauricio, Didac , Schloot, Nanette C , Khunti, Kamlesh , Greenbaum, Carla J , Hansen, Torben , Tuomi, Tiinamaija , Leslie, R David , Froguel, Phillippe , Grant, Struan F A , Ahlqvist, Emma , Snyder, James, Pratley, Richard E. , Vella, Adrian , Ovalle, Fernando , Lonsdale, John T., Study, Bone Mineral Density in Childhood, McCormack, Shana Erin , Kelly, Andrea True , Kalkwarf, Heidi J. , Shepherd, John , Oberfield, Sharon E. , Zemel, Babette S.

Mayo Clinic

Diabetes Care | September 25, 2018 | Volume: 41 | Issue: 11 | Pages: 2396-2403

10.2337/dc18-1032 | PMID 30254083 Get It

OBJECTIVELatent autoimmune diabetes in adults (LADA) shares clinical features with both type 1 and type 2 diabetes; however, there is ongoing debate regarding the precise definition of LADA. Understanding its genetic basis is one potential strategy to gain insight into appropriate classification of this diabetes subtype.RESEARCH DESIGN AND METHODSWe performed the first genome-wide association study of LADA in case subjects of European ancestry versus population control subjects (n = 2,634 vs. 5,947) and compared against both case subjects with type 1 diabetes (n = 2,454 vs. 968) and type 2 diabetes (n = 2,779 vs. 10,396).RESULTSThe leading genetic signals were principally shared with type 1 diabetes, although we observed positive genetic correlations genome-wide with both type 1 and type 2 diabetes. Additionally, we observed a novel independent signal at the known type 1 diabetes locus harboring PFKFB3, encoding a regulator of glycolysis and insulin signaling in type 2 diabetes and inflammation and autophagy in autoimmune disease, as well as an attenuation of key type 1–associated HLA haplotype frequencies in LADA, suggesting that these are factors that distinguish childhood-onset type 1 diabetes from adult autoimmune diabetes.CONCLUSIONSOur results support the need for further investigations of the genetic factors that distinguish forms of autoimmune diabetes as well as more precise classification strategies.
Impaired Autophagy of GABAergic Interneurons in Neuropathic Pain
Yin, Yuhua , Yi, Min‐Hee , Kim, Dong Woon , Kim, Dong Woon

Mayo Clinic

Pain Research and Management | September 25, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/9185368 | PMID 30356379 Get It

Neuropathic pain (NP) is caused by lesions of the peripheral fibers and central neurons in the somatosensory nervous system and affects 7–10% of the general population. Although the distinct cause of neuropathic pain has been investigated in primary afferent neurons over the years, pain modulation by central sensitization remains controversial. NP is believed to be driven by cell type-specific spinal synaptic plasticity in the dorsal horn. Upon intense afferent stimulation, spinothalamic tract neurons are potentiated, whereas GABAergic interneurons are inhibited leading to long-term depression. Growing evidences suggest that the inhibition of GABAergic neurons plays pivotal roles in the manifestation of neuropathic and inflammatory pain states. Downregulation of GABA transmission and impairment of GABAergic interneurons in the dorsal horn are critical consequences after spinal cord and peripheral nerve injuries. These impairments in GABAergic interneurons may be associated with dysfunctional autophagy, resulting in neuropathic pain. Here, we review an emerging number of investigations that suggest a pivotal role of impaired autophagy of GABAergic interneurons in NP. We discuss relevant research spurring the development of new targets and therapeutic agents of NP and emphasize the need for a multidisciplinary approach to manage NP in the future.
Trigeminal Nerve Schwannoma of the Cerebellopontine Angle
Peris‐Celda, Maria , Graffeo, Christopher S. , Perry, Avital , Link, Michael J. , Carlstrom, Lucas P.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | September 25, 2018 | Volume: 79 | Issue: S 05 | Pages: S389-S390

10.1055/s-0038-1669966 | PMID 30456035 Get It

Introduction Large and even moderate sized, extra-axial cerebellopontine angle (CPA) tumors may fill this restricted space and distort the regional anatomy. It may be difficult to determine even with high resolution magnetic resonance imaging (MRI) if the tumor is dural-based, or what the nerve of origin is if a schwannoma. While clinical history and exam are helpful, they are not unequivocal, particularly since many patients present with a myriad of symptoms, or conversely an incidental finding. We present an atypical appearing, asymptomatic CPA tumor, ultimately identified at surgery to be a trigeminal schwannoma. Case History A 40-year-old man presented with new-onset seizure. MRI identified an incidental heterogeneously contrast-enhancing CPA lesion (Fig. 1A–D). The tumor was centered on the internal auditory canal (IAC) with no tumor extension into Meckel's cave, IAC or jugular foramen. Audiometry demonstrated 10db of relative left-sided hearing loss with 100% word recognition. Physical examination was negative for focal neurologic deficits. A retrosigmoid craniotomy was performed and an extra-axial, yellow-hued mass was encountered and resected, which was ultimately confirmed to originate from the trigeminal nerve (Video 1). Gross total resection was achieved, and the patient recovered from surgery with partial ipsilateral trigeminal sensory loss and no other new neurologic deficits. Conclusion Pure CPA trigeminal schwannomas are rare, but should be considered in the differential for enhancing CPA lesions. Although, Meckel's cave involvement is frequently observed, it is not universal, and pure CPA schwannomas of all cranial nerves IV–XII have been reported in the literature.The link to the video can be found at: https://youtu.be/AlodYCu70F8.
Author Disclosures in Plastic Surgery Journals Compared With Information Reported in the Open Payments Database: How Open Are We?
Boyll, Piper, Neville, Matthew R., Bernard, Robert W. , Mahabir, Raman C. , Neville, Matthew, Bernard, Robert

Mayo Clinic

Aesthetic Surgery Journal | September 25, 2018 | Volume: 39 | Issue: 3 | Pages: 338-342

10.1093/asj/sjy218 | PMID 30256895 Get It

Abstract Background Relationships between companies in the biomedical industry and authors submitting scientific articles for publication has been an issue of some concern for many years. It has been frequently demonstrated that these financial relationships can influence the manner in which research findings are presented. The National Physician Payment Transparency Program, also known as the Open Payment Program or the Sunshine Act, was legislated to expose potential conflicts of interest (COIs). Likewise, most peer-reviewed journals require disclosure of any potential COIs. Objectives The purpose of this paper was to compare the information published in the Open Payment Database to authors’ self-disclosed COIs in their published articles. Methods An analysis was performed by one of the authors (P.S.B.) of all articles published in Aesthetic Surgery Journal (ASJ) and Plastic and Reconstructive Surgery (PRS) from August 2013 through December 2016. Financial disclosures reported in these articles were compared with the physician payment information provided by the biomedical industry and published in the Open Payments Database in 2013 and 2018. Results A total of 1346 articles were included in the study, from which 320 authors and 899 total authorships were eligible for analysis. Out of 782 authorships with noted discrepancies, 96% were related to potential COIs found in the Open Payments database but not disclosed in the journal publication. Conclusions Our data suggest major discordance between authors’ self-reported COIs in the plastic surgery literature and industry payments published in the Open Payments database.